Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Three Territory Sign
Neurol Clin Pract 9:124-128, Nouh, A.M.,et al, 2019
D-Dimer as a Predictor of Early Neurologic Deterioration in Cryptogenic Stroke with Active Cancer
Eur J Neurol 24:205-211, Nam, K.-W.,et al, 2017
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant
J Stroke Cerebrovasc Dis 26:2976-2980, Nam, K.W.,et al, 2017
Clinicopathologic Conference, Acute Ischemic Stroke, Caused by Paradoxical Embolism Through a Patent Foramen Ovale, in a Patient with the May-Thurner Syndrome and a Hypercoagulable State Due to an Occult Renal-Cell Carcinoma
NEJM 374:1671-1680, Case 13-2016, 2016
Characteristics of Cryptogenic Stroke in Cancer Patients
Ann Clin Trans Neurol 3:280-287, Gon, Y.,et al, 2016
Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Evaluation of Cryptogenic Stroke with Advanced Diagnostic Techniques
Stroke 45:1186-1194, Bang, O.Y.,et al, 2014
Stroke and Cancer - A Complicated Relationship
J Neurol Transl Neurosci 2:1039-1051, Dearborn, J.L.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Patent Foramen Ovale in Young Adults with Unexplained Stroke
NEJM 353:2361-2372, Kizer,J.R. &Devereux,R.B., 2005
Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients with Patent Foramen Ovale
Stroke 35:2145, Homma,S.,et al, 2004